Details of the Drug

General Information of Drug (ID: DMH7OIA)

Drug Name
Infliximab
Synonyms Remicade (TN)
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [1]
Lupus nephritis 4A40.0Y Approved [2]
Plaque psoriasis EA90.0 Approved [3]
Psoriatic arthritis FA21 Approved [4]
Toxic epidermal necrolysis N.A. Approved [5]
Ulcerative colitis DD71 Approved [6]
Asthma CA23 Phase 3 [3]
Rheumatoid arthritis FA20 Phase 2 [7]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [8]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Immunosuppressive Agents
Affected Organisms
Humans and other mammals
ATC Code
L04AB02: Infliximab
L04AB: Tumor necrosis factor alpha (TNF-) inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 75 mg/L [9]
Clearance
The total body clearance of drug is 18.4 mL/h [9]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.7 - 9.5 days []
Vd
The volume of distribution (Vd) of drug is 0.08 L/kg [9]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
ACR20 response rs1801274 FCGR3A OTOWXCF3 [10]
Cross-matching ID
UNII
B72HH48FLU
DrugBank ID
DB00065
TTD ID
D0PG5G
VARIDT ID
DR00451
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Not Available [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A) OTOWXCF3 FCG3A_HUMAN Drug Response [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Crohn disease
ICD Disease Classification DD70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 1.24E-17 0.42 1.18
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Infliximab
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Brodalumab DMASDQ6 Major Additive immunosuppressive effects by the combination of Infliximab and Brodalumab. Psoriasis [EA90] [12]
Efalizumab DMCKL5V Moderate Additive immunosuppressive effects by the combination of Infliximab and Efalizumab. Psoriasis [EA90] [13]
Ustekinumab DMHTYK3 Major Additive immunosuppressive effects by the combination of Infliximab and Ustekinumab. Psoriasis [EA90] [12]
Tildrakizumab DMLW9HG Major Additive immunosuppressive effects by the combination of Infliximab and Tildrakizumab. Psoriasis [EA90] [12]
Risankizumab DMM32GT Major Additive immunosuppressive effects by the combination of Infliximab and Risankizumab. Psoriasis [EA90] [12]
Ixekizumab DMXW92T Major Additive immunosuppressive effects by the combination of Infliximab and Ixekizumab. Psoriasis [EA90] [12]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Infliximab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [14]
Thioguanine DM7NKEV Major Additive immunosuppressive effects by the combination of Infliximab and Thioguanine. Acute myeloid leukaemia [2A60] [12]
Uracil mustard DMHL7OB Major Additive immunosuppressive effects by the combination of Infliximab and Uracil mustard. Acute myeloid leukaemia [2A60] [12]
Midostaurin DMI6E0R Major Additive immunosuppressive effects by the combination of Infliximab and Midostaurin. Acute myeloid leukaemia [2A60] [12]
Idarubicin DMM0XGL Major Additive immunosuppressive effects by the combination of Infliximab and Idarubicin. Acute myeloid leukaemia [2A60] [12]
Daunorubicin DMQUSBT Major Additive immunosuppressive effects by the combination of Infliximab and Daunorubicin. Acute myeloid leukaemia [2A60] [12]
Oliceridine DM6MDCF Moderate Altered metabolism of Infliximab due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [15]
Siltuximab DMGEATB Major Additive immunosuppressive effects by the combination of Infliximab and Siltuximab. Anemia [3A00-3A9Z] [12]
Nifedipine DMSVOZT Moderate Altered metabolism of Infliximab due to Nifedipine alters the formation of CYP450 enzymes. Angina pectoris [BA40] [15]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Alprazolam DMC7XDN Moderate Altered metabolism of Infliximab due to Alprazolam alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [15]
Methylphenobarbital DMDSWAG Moderate Altered metabolism of Infliximab due to Methylphenobarbital alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [17]
Clobazam - Lundbeck DMW1OQ0 Moderate Altered metabolism of Infliximab due to Clobazam - Lundbeck alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [15]
Budesonide DMJIBAW Major Additive immunosuppressive effects by the combination of Infliximab and Budesonide. Asthma [CA23] [12]
Aminophylline DML2NIB Moderate Altered metabolism of Infliximab due to Aminophylline alters the formation of CYP450 enzymes. Asthma [CA23] [15]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Infliximab and Roflumilast. Asthma [CA23] [15]
Dupilumab DMOAD2Y Major Additive immunosuppressive effects by the combination of Infliximab and Dupilumab. Atopic eczema [EA80] [12]
Linezolid DMGFPU2 Major Additive immunosuppressive effects by the combination of Infliximab and Linezolid. Bacterial infection [1A00-1C4Z] [12]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Infliximab and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [18]
Temozolomide DMKECZD Major Additive immunosuppressive effects by the combination of Infliximab and Temozolomide. Brain cancer [2A00] [12]
Lomustine DMMWSUL Major Additive immunosuppressive effects by the combination of Infliximab and Lomustine. Brain cancer [2A00] [12]
Eribulin DM1DX4Q Major Additive immunosuppressive effects by the combination of Infliximab and Eribulin. Breast cancer [2C60-2C6Y] [12]
Talazoparib DM1KS78 Major Additive immunosuppressive effects by the combination of Infliximab and Talazoparib. Breast cancer [2C60-2C6Y] [12]
Ixabepilone DM2OZ3G Major Additive immunosuppressive effects by the combination of Infliximab and Ixabepilone. Breast cancer [2C60-2C6Y] [12]
LY2835219 DM93VBZ Major Additive immunosuppressive effects by the combination of Infliximab and LY2835219. Breast cancer [2C60-2C6Y] [12]
Pralatrexate DMAO80I Major Additive immunosuppressive effects by the combination of Infliximab and Pralatrexate. Breast cancer [2C60-2C6Y] [12]
Palbociclib DMD7L94 Major Additive immunosuppressive effects by the combination of Infliximab and Palbociclib. Breast cancer [2C60-2C6Y] [12]
Mitomycin DMH0ZJE Major Additive immunosuppressive effects by the combination of Infliximab and Mitomycin. Breast cancer [2C60-2C6Y] [12]
Thiotepa DMIZKOP Major Additive immunosuppressive effects by the combination of Infliximab and Thiotepa. Breast cancer [2C60-2C6Y] [12]
Cabazitaxel DMPAZHC Major Additive immunosuppressive effects by the combination of Infliximab and Cabazitaxel. Breast cancer [2C60-2C6Y] [12]
Bosutinib DMTI8YE Major Additive immunosuppressive effects by the combination of Infliximab and Bosutinib. Breast cancer [2C60-2C6Y] [12]
Trastuzumab DMZQOUX Major Additive immunosuppressive effects by the combination of Infliximab and Trastuzumab. Breast cancer [2C60-2C6Y] [12]
Atorvastatin DMF28YC Moderate Altered metabolism of Infliximab due to Atorvastatin alters the formation of CYP450 enzymes. Cardiovascular disease [BA00-BE2Z] [15]
Corticotropin DMP9TWZ Major Additive immunosuppressive effects by the combination of Infliximab and Corticotropin. Chronic kidney disease [GB61] [12]
Irinotecan DMP6SC2 Major Additive immunosuppressive effects by the combination of Infliximab and Irinotecan. Colorectal cancer [2B91] [12]
Oxaliplatin DMQNWRD Major Additive immunosuppressive effects by the combination of Infliximab and Oxaliplatin. Colorectal cancer [2B91] [12]
Aflibercept DMT3D5I Major Additive immunosuppressive effects by the combination of Infliximab and Aflibercept. Colorectal cancer [2B91] [12]
Capecitabine DMTS85L Major Additive immunosuppressive effects by the combination of Infliximab and Capecitabine. Colorectal cancer [2B91] [12]
Drospirenone DM1A9W3 Moderate Altered metabolism of Infliximab due to Drospirenone alters the formation of CYP450 enzymes. Contraceptive management [QA21] [15]
Levonorgestrel DM1DP7T Moderate Altered metabolism of Infliximab due to Levonorgestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [15]
Desogestrel DM27U4Y Moderate Altered metabolism of Infliximab due to Desogestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [17]
Norgestimate DMYP4XC Moderate Altered metabolism of Infliximab due to Norgestimate alters the formation of CYP450 enzymes. Contraceptive management [QA21] [17]
Lidocaine DML4ZOT Moderate Altered metabolism of Infliximab due to Lidocaine alters the formation of CYP450 enzymes. Corneal disease [9A76-9A78] [15]
Nimodipine DMQ0RKZ Moderate Altered metabolism of Infliximab due to Nimodipine alters the formation of CYP450 enzymes. Coronary vasospastic disease [BA85] [15]
Oxtriphylline DMLHSE3 Moderate Altered metabolism of Infliximab due to Oxtriphylline alters the formation of CYP450 enzymes. Cough [MD12] [15]
Methadone DMTW6IU Moderate Altered metabolism of Infliximab due to Methadone alters the formation of CYP450 enzymes. Cough [MD12] [15]
Mycophenolic acid DMRBMAU Major Additive immunosuppressive effects by the combination of Infliximab and Mycophenolic acid. Crohn disease [DD70] [12]
Rivaroxaban DMQMBZ1 Moderate Altered metabolism of Infliximab due to Rivaroxaban alters the formation of CYP450 enzymes. Deep vein thrombosis [BD71] [15]
Polatuzumab vedotin DMF6Y0L Major Additive immunosuppressive effects by the combination of Infliximab and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [12]
Lisocabtagene maraleucel DMP45ME Major Additive immunosuppressive effects by the combination of Infliximab and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [12]
PMID28870136-Compound-48 DMPIM9L Moderate Altered metabolism of Infliximab due to PMID28870136-Compound-48 alters the formation of CYP450 enzymes. Discovery agent [N.A.] [15]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered metabolism of Infliximab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. Endometriosis [GA10] [17]
Diazepam DM08E9O Moderate Altered metabolism of Infliximab due to Diazepam alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Primidone DM0WX6I Moderate Altered metabolism of Infliximab due to Primidone alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Mephenytoin DM5UGDK Moderate Altered metabolism of Infliximab due to Mephenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Ethosuximide DMDZ9LT Moderate Altered metabolism of Infliximab due to Ethosuximide alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Phenytoin DMNOKBV Moderate Altered metabolism of Infliximab due to Phenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Fosphenytoin DMOX3LB Moderate Altered metabolism of Infliximab due to Fosphenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Clonazepam DMTO13J Moderate Altered metabolism of Infliximab due to Clonazepam alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Phenobarbital DMXZOCG Moderate Altered metabolism of Infliximab due to Phenobarbital alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Carbamazepine DMZOLBI Moderate Altered metabolism of Infliximab due to Carbamazepine alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [15]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Cannabidiol. Epileptic encephalopathy [8A62] [15]
Nicardipine DMCDYW7 Moderate Altered metabolism of Infliximab due to Nicardipine alters the formation of CYP450 enzymes. Essential hypertension [BA00] [15]
Bay 80-6946 DMLOS5R Major Additive immunosuppressive effects by the combination of Infliximab and Bay 80-6946. Follicular lymphoma [2A80] [12]
Avapritinib DMK2GZX Major Additive immunosuppressive effects by the combination of Infliximab and Avapritinib. Gastrointestinal stromal tumour [2B5B] [12]
177Lu-DOTATATE DMT8GVU Major Additive immunosuppressive effects by the combination of Infliximab and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [12]
Bleomycin DMNER5S Major Additive immunosuppressive effects by the combination of Infliximab and Bleomycin. Hodgkin lymphoma [2B30] [12]
Brentuximab vedotin DMWLC57 Major Additive immunosuppressive effects by the combination of Infliximab and Brentuximab vedotin. Hodgkin lymphoma [2B30] [12]
Zidovudine DM4KI7O Major Additive immunosuppressive effects by the combination of Infliximab and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [12]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [19]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Infliximab and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [20]
Simvastatin DM30SGU Moderate Altered metabolism of Infliximab due to Simvastatin alters the formation of CYP450 enzymes. Hyper-lipoproteinaemia [5C80] [15]
Lovastatin DM9OZWQ Moderate Altered metabolism of Infliximab due to Lovastatin alters the formation of CYP450 enzymes. Hyper-lipoproteinaemia [5C80] [15]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Infliximab and Mipomersen. Hyper-lipoproteinaemia [5C80] [21]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Infliximab and BMS-201038. Hyper-lipoproteinaemia [5C80] [22]
Nisoldipine DM7ISKJ Moderate Altered metabolism of Infliximab due to Nisoldipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [15]
Levamlodipine DM92S6N Moderate Altered metabolism of Infliximab due to Levamlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [15]
Isradipine DMA5XGH Moderate Altered metabolism of Infliximab due to Isradipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [15]
Amlodipine DMBDAZV Moderate Altered metabolism of Infliximab due to Amlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [15]
Felodipine DMOSW35 Moderate Altered metabolism of Infliximab due to Felodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [15]
Fludrocortisone DMUDIR8 Major Additive immunosuppressive effects by the combination of Infliximab and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [12]
Triazolam DMETYK5 Moderate Altered metabolism of Infliximab due to Triazolam alters the formation of CYP450 enzymes. Insomnia [7A00-7A0Z] [15]
Olaratumab DMNYOIX Major Additive immunosuppressive effects by the combination of Infliximab and Olaratumab. Kaposi sarcoma [2B57] [12]
Methotrexate DM2TEOL Major Additive immunosuppressive effects by the combination of Infliximab and Methotrexate. Leukaemia [2A60-2B33] [12]
Nelarabine DMB6VEG Major Additive immunosuppressive effects by the combination of Infliximab and Nelarabine. Leukaemia [2A60-2B33] [12]
DTI-015 DMXZRW0 Major Additive immunosuppressive effects by the combination of Infliximab and DTI-015. Liver cancer [2C12] [12]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Infliximab and Denosumab. Low bone mass disorder [FB83] [23]
Brigatinib DM7W94S Major Additive immunosuppressive effects by the combination of Infliximab and Brigatinib. Lung cancer [2C25] [12]
Lurbinectedin DMEFRTZ Major Additive immunosuppressive effects by the combination of Infliximab and Lurbinectedin. Lung cancer [2C25] [12]
Osimertinib DMRJLAT Major Additive immunosuppressive effects by the combination of Infliximab and Osimertinib. Lung cancer [2C25] [12]
Belimumab DM3OBQF Major Additive immunosuppressive effects by the combination of Infliximab and Belimumab. Lupus erythematosus [4A40] [12]
Primaquine DMWQ16I Major Additive immunosuppressive effects by the combination of Infliximab and Primaquine. Malaria [1F40-1F45] [12]
Inotuzumab ozogamicin DMAC130 Major Additive immunosuppressive effects by the combination of Infliximab and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [12]
Rituximab DM1YVZT Major Additive immunosuppressive effects by the combination of Infliximab and Rituximab. Malignant haematopoietic neoplasm [2B33] [12]
Tositumomab DMMYZ3D Major Additive immunosuppressive effects by the combination of Infliximab and Tositumomab. Malignant haematopoietic neoplasm [2B33] [12]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [24]
Fludarabine DMVRLT7 Major Additive immunosuppressive effects by the combination of Infliximab and Fludarabine. Malignant haematopoietic neoplasm [2B33] [12]
Pentostatin DM0HXDS Major Additive immunosuppressive effects by the combination of Infliximab and Pentostatin. Mature B-cell leukaemia [2A82] [12]
Ofatumumab DM295PR Major Additive immunosuppressive effects by the combination of Infliximab and Ofatumumab. Mature B-cell leukaemia [2A82] [12]
Obinutuzumab DM3BVAE Major Additive immunosuppressive effects by the combination of Infliximab and Obinutuzumab. Mature B-cell leukaemia [2A82] [12]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Infliximab and Cladribine. Mature B-cell leukaemia [2A82] [15]
Idelalisib DM602WT Major Additive immunosuppressive effects by the combination of Infliximab and Idelalisib. Mature B-cell leukaemia [2A82] [12]
Chlorambucil DMRKE63 Major Additive immunosuppressive effects by the combination of Infliximab and Chlorambucil. Mature B-cell leukaemia [2A82] [12]
IPI-145 DMWA24P Major Additive immunosuppressive effects by the combination of Infliximab and IPI-145. Mature B-cell leukaemia [2A82] [12]
Alemtuzumab DMZL3IV Moderate Additive immunosuppressive effects by the combination of Infliximab and Alemtuzumab. Mature B-cell leukaemia [2A82] [25]
Acalabrutinib DM7GCVW Major Additive immunosuppressive effects by the combination of Infliximab and Acalabrutinib. Mature B-cell lymphoma [2A85] [12]
Clofarabine DMCVJ86 Major Additive immunosuppressive effects by the combination of Infliximab and Clofarabine. Mature B-cell lymphoma [2A85] [12]
Blinatumomab DMGECIJ Major Additive immunosuppressive effects by the combination of Infliximab and Blinatumomab. Mature B-cell lymphoma [2A85] [12]
Ibrutinib DMHZCPO Major Additive immunosuppressive effects by the combination of Infliximab and Ibrutinib. Mature B-cell lymphoma [2A85] [12]
Vincristine DMINOX3 Major Additive immunosuppressive effects by the combination of Infliximab and Vincristine. Mature B-cell lymphoma [2A85] [12]
Teniposide DMLW57T Major Additive immunosuppressive effects by the combination of Infliximab and Teniposide. Mature B-cell lymphoma [2A85] [12]
Tisagenlecleucel DMM9BJD Major Additive immunosuppressive effects by the combination of Infliximab and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [12]
Mercaptopurine DMTM2IK Major Additive immunosuppressive effects by the combination of Infliximab and Mercaptopurine. Mature B-cell lymphoma [2A85] [12]
Ponatinib DMYGJQO Major Additive immunosuppressive effects by the combination of Infliximab and Ponatinib. Mature B-cell lymphoma [2A85] [12]
Cytarabine DMZD5QR Major Additive immunosuppressive effects by the combination of Infliximab and Cytarabine. Mature B-cell lymphoma [2A85] [12]
Mechlorethamine DM0CVXA Major Additive immunosuppressive effects by the combination of Infliximab and Mechlorethamine. Mature T-cell lymphoma [2A90] [12]
Dacarbazine DMNPZL4 Major Additive immunosuppressive effects by the combination of Infliximab and Dacarbazine. Melanoma [2C30] [12]
Ethinyl estradiol DMODJ40 Moderate Altered metabolism of Infliximab due to Ethinyl estradiol alters the formation of CYP450 enzymes. Menopausal disorder [GA30] [17]
Midazolam DMXOELT Moderate Altered metabolism of Infliximab due to Midazolam alters the formation of CYP450 enzymes. Mood/affect symptom [MB24] [15]
Carfilzomib DM48K0X Major Additive immunosuppressive effects by the combination of Infliximab and Carfilzomib. Multiple myeloma [2A83] [12]
Panobinostat DM58WKG Major Additive immunosuppressive effects by the combination of Infliximab and Panobinostat. Multiple myeloma [2A83] [12]
Thalidomide DM70BU5 Major Additive immunosuppressive effects by the combination of Infliximab and Thalidomide. Multiple myeloma [2A83] [12]
Selinexor DMBD4K3 Major Additive immunosuppressive effects by the combination of Infliximab and Selinexor. Multiple myeloma [2A83] [12]
Belantamab mafodotin DMBT3AI Major Additive immunosuppressive effects by the combination of Infliximab and Belantamab mafodotin. Multiple myeloma [2A83] [12]
Elotuzumab DMEYHG9 Major Additive immunosuppressive effects by the combination of Infliximab and Elotuzumab. Multiple myeloma [2A83] [12]
Daratumumab DMKCIUZ Major Additive immunosuppressive effects by the combination of Infliximab and Daratumumab. Multiple myeloma [2A83] [12]
Bortezomib DMNO38U Major Additive immunosuppressive effects by the combination of Infliximab and Bortezomib. Multiple myeloma [2A83] [12]
Melphalan DMOLNHF Major Additive immunosuppressive effects by the combination of Infliximab and Melphalan. Multiple myeloma [2A83] [12]
Tecfidera DM2OVDT Major Additive immunosuppressive effects by the combination of Infliximab and Tecfidera. Multiple sclerosis [8A40] [12]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Infliximab and Fingolimod. Multiple sclerosis [8A40] [26]
Interferon beta-1b DMCN61Z Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Interferon beta-1b. Multiple sclerosis [8A40] [27]
Ocrelizumab DMEZ2KH Major Additive immunosuppressive effects by the combination of Infliximab and Ocrelizumab. Multiple sclerosis [8A40] [12]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Infliximab and Ozanimod. Multiple sclerosis [8A40] [15]
Deflazacort DMV0RNS Major Additive immunosuppressive effects by the combination of Infliximab and Deflazacort. Muscular dystrophy [8C70] [12]
Bexarotene DMOBIKY Major Additive immunosuppressive effects by the combination of Infliximab and Bexarotene. Mycosis fungoides [2B01] [12]
Romidepsin DMT5GNL Major Additive immunosuppressive effects by the combination of Infliximab and Romidepsin. Mycosis fungoides [2B01] [12]
Decitabine DMQL8XJ Major Additive immunosuppressive effects by the combination of Infliximab and Decitabine. Myelodysplastic syndrome [2A37] [12]
Azacitidine DMTA5OE Major Additive immunosuppressive effects by the combination of Infliximab and Azacitidine. Myelodysplastic syndrome [2A37] [12]
Nilotinib DM7HXWT Major Additive immunosuppressive effects by the combination of Infliximab and Nilotinib. Myeloproliferative neoplasm [2A20] [12]
Ruxolitinib DM7Q98D Major Additive immunosuppressive effects by the combination of Infliximab and Ruxolitinib. Myeloproliferative neoplasm [2A20] [12]
Dasatinib DMJV2EK Major Additive immunosuppressive effects by the combination of Infliximab and Dasatinib. Myeloproliferative neoplasm [2A20] [12]
Hydroxyurea DMOQVU9 Major Additive immunosuppressive effects by the combination of Infliximab and Hydroxyurea. Myeloproliferative neoplasm [2A20] [12]
Omacetaxine mepesuccinate DMPU2WX Major Additive immunosuppressive effects by the combination of Infliximab and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [12]
Busulfan DMXYJ9C Major Additive immunosuppressive effects by the combination of Infliximab and Busulfan. Myeloproliferative neoplasm [2A20] [12]
Inebilizumab DMI0RHA Major Additive immunosuppressive effects by the combination of Infliximab and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [12]
Atezolizumab DMMF8U0 Major Additive immunosuppressive effects by the combination of Infliximab and Atezolizumab. Non-small cell lung cancer [2C25] [12]
Olaparib DM8QB1D Major Additive immunosuppressive effects by the combination of Infliximab and Olaparib. Ovarian cancer [2C73] [12]
Carboplatin DMG281S Major Additive immunosuppressive effects by the combination of Infliximab and Carboplatin. Ovarian cancer [2C73] [12]
Altretamine DMKLAYG Major Additive immunosuppressive effects by the combination of Infliximab and Altretamine. Ovarian cancer [2C73] [12]
MK-4827 DMLYGH4 Major Additive immunosuppressive effects by the combination of Infliximab and MK-4827. Ovarian cancer [2C73] [12]
Topotecan DMP6G8T Major Additive immunosuppressive effects by the combination of Infliximab and Topotecan. Ovarian cancer [2C73] [12]
Buprenorphine DMPRI8G Moderate Altered metabolism of Infliximab due to Buprenorphine alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [15]
Hydrocodone DMQ2JO5 Moderate Altered metabolism of Infliximab due to Hydrocodone alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [15]
Oxycodone DMXLKHV Moderate Altered metabolism of Infliximab due to Oxycodone alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [15]
Streptozocin DMOF7AT Major Additive immunosuppressive effects by the combination of Infliximab and Streptozocin. Pancreatic cancer [2C10] [12]
Levamisole DM5EN79 Major Additive immunosuppressive effects by the combination of Infliximab and Levamisole. Parasitic infection [1D0Y-1G2Z] [12]
Pemetrexed DMMX2E6 Major Additive immunosuppressive effects by the combination of Infliximab and Pemetrexed. Pleural mesothelioma [2C26] [12]
Prednisone DM2HG4X Major Additive immunosuppressive effects by the combination of Infliximab and Prednisone. Postoperative inflammation [1A00-CA43] [12]
Betamethasone DMAHJEF Major Additive immunosuppressive effects by the combination of Infliximab and Betamethasone. Postoperative inflammation [1A00-CA43] [12]
Hydrocortisone DMGEMB7 Major Additive immunosuppressive effects by the combination of Infliximab and Hydrocortisone. Postoperative inflammation [1A00-CA43] [12]
Everolimus DM8X2EH Major Additive immunosuppressive effects by the combination of Infliximab and Everolimus. Renal cell carcinoma [2C90] [12]
Temsirolimus DMS104F Major Additive immunosuppressive effects by the combination of Infliximab and Temsirolimus. Renal cell carcinoma [2C90] [12]
Upadacitinib DM32B5U Major Additive immunosuppressive effects by the combination of Infliximab and Upadacitinib. Rheumatoid arthritis [FA20] [15]
Canakinumab DM8HLO5 Major Additive immunosuppressive effects by the combination of Infliximab and Canakinumab. Rheumatoid arthritis [FA20] [14]
Rilonacept DMGLUQS Major Additive immunosuppressive effects by the combination of Infliximab and Rilonacept. Rheumatoid arthritis [FA20] [14]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Infliximab and Golimumab. Rheumatoid arthritis [FA20] [12]
Dexamethasone DMMWZET Major Additive immunosuppressive effects by the combination of Infliximab and Dexamethasone. Rheumatoid arthritis [FA20] [12]
Abatacept DMSA8RU Major Additive immunosuppressive effects by the combination of Infliximab and Abatacept. Rheumatoid arthritis [FA20] [28]
Fentanyl DM8WAHT Moderate Altered metabolism of Infliximab due to Fentanyl alters the formation of CYP450 enzymes. Sensation disturbance [MB40] [15]
Sufentanil DMU7YEL Moderate Altered metabolism of Infliximab due to Sufentanil alters the formation of CYP450 enzymes. Sensation disturbance [MB40] [15]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Infliximab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [29]
Mogamulizumab DMISH0Z Major Additive immunosuppressive effects by the combination of Infliximab and Mogamulizumab. Sezary syndrome [2B02] [12]
Floxuridine DM04LR2 Major Additive immunosuppressive effects by the combination of Infliximab and Floxuridine. Solid tumour/cancer [2A00-2F9Z] [12]
Dactinomycin DM2YGNW Major Additive immunosuppressive effects by the combination of Infliximab and Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [12]
Methylprednisolone DM4BDON Major Additive immunosuppressive effects by the combination of Infliximab and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [12]
Cyclophosphamide DM4O2Z7 Major Additive immunosuppressive effects by the combination of Infliximab and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [12]
Vinblastine DM5TVS3 Major Additive immunosuppressive effects by the combination of Infliximab and Vinblastine. Solid tumour/cancer [2A00-2F9Z] [12]
PDX-101 DM6OC53 Major Additive immunosuppressive effects by the combination of Infliximab and PDX-101. Solid tumour/cancer [2A00-2F9Z] [12]
Ifosfamide DMCT3I8 Major Additive immunosuppressive effects by the combination of Infliximab and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [12]
Docetaxel DMDI269 Major Additive immunosuppressive effects by the combination of Infliximab and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [12]
Trabectedin DMG3Y89 Major Additive immunosuppressive effects by the combination of Infliximab and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [12]
Mitoxantrone DMM39BF Major Additive immunosuppressive effects by the combination of Infliximab and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [12]
LEE011 DMMX75K Major Additive immunosuppressive effects by the combination of Infliximab and LEE011. Solid tumour/cancer [2A00-2F9Z] [12]
Etoposide DMNH3PG Major Additive immunosuppressive effects by the combination of Infliximab and Etoposide. Solid tumour/cancer [2A00-2F9Z] [12]
Epirubicin DMPDW6T Major Additive immunosuppressive effects by the combination of Infliximab and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Prednisolone DMQ8FR2 Major Additive immunosuppressive effects by the combination of Infliximab and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [12]
Cisplatin DMRHGI9 Major Additive immunosuppressive effects by the combination of Infliximab and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [12]
Gemcitabine DMSE3I7 Major Additive immunosuppressive effects by the combination of Infliximab and Gemcitabine. Solid tumour/cancer [2A00-2F9Z] [12]
Norethindrone DMTY169 Moderate Altered metabolism of Infliximab due to Norethindrone alters the formation of CYP450 enzymes. Solid tumour/cancer [2A00-2F9Z] [17]
Fluorouracil DMUM7HZ Major Additive immunosuppressive effects by the combination of Infliximab and Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [12]
Taxol DMUOT9V Major Additive immunosuppressive effects by the combination of Infliximab and Taxol. Solid tumour/cancer [2A00-2F9Z] [12]
Doxorubicin DMVP5YE Major Additive immunosuppressive effects by the combination of Infliximab and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Vinorelbine DMVXFYE Major Additive immunosuppressive effects by the combination of Infliximab and Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [12]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Infliximab and Naltrexone. Substance abuse [6C40] [30]
Warfarin DMJYCVW Moderate Altered metabolism of Infliximab due to Warfarin alters the formation of CYP450 enzymes. Supraventricular tachyarrhythmia [BC81] [15]
Pomalidomide DMTGBAX Major Additive immunosuppressive effects by the combination of Infliximab and Pomalidomide. Systemic sclerosis [4A42] [12]
Plicamycin DM7C8YV Major Additive immunosuppressive effects by the combination of Infliximab and Plicamycin. Testicular cancer [2C80] [12]
Apixaban DM89JLN Moderate Altered metabolism of Infliximab due to Apixaban alters the formation of CYP450 enzymes. Thrombosis [DB61-GB90] [15]
Trimetrexate DMDEA85 Major Additive immunosuppressive effects by the combination of Infliximab and Trimetrexate. Toxoplasmosis [1F57] [12]
Muromonab DM8ANCF Major Additive immunosuppressive effects by the combination of Infliximab and Muromonab. Transplant rejection [NE84] [12]
Sirolimus DMGW1ID Major Additive immunosuppressive effects by the combination of Infliximab and Sirolimus. Transplant rejection [NE84] [12]
Azathioprine DMMZSXQ Major Additive immunosuppressive effects by the combination of Infliximab and Azathioprine. Transplant rejection [NE84] [12]
Mycophenolate mofetil DMPQAGE Major Additive immunosuppressive effects by the combination of Infliximab and Mycophenolate mofetil. Transplant rejection [NE84] [12]
Basiliximab DMWNRZT Major Additive immunosuppressive effects by the combination of Infliximab and Basiliximab. Transplant rejection [NE84] [12]
Belatacept DMXLYQF Major Additive immunosuppressive effects by the combination of Infliximab and Belatacept. Transplant rejection [NE84] [12]
Tacrolimus DMZ7XNQ Major Additive immunosuppressive effects by the combination of Infliximab and Tacrolimus. Transplant rejection [NE84] [12]
Durvalumab DM4PVDY Major Additive immunosuppressive effects by the combination of Infliximab and Durvalumab. Ureteral cancer [2C92] [12]
Triamcinolone DM98IXF Major Additive immunosuppressive effects by the combination of Infliximab and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [12]
Disopyramide DM5SYZP Moderate Altered metabolism of Infliximab due to Disopyramide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [15]
Mexiletine DMCTE9R Moderate Altered metabolism of Infliximab due to Mexiletine alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [15]
Procainamide DMNMXR8 Moderate Altered metabolism of Infliximab due to Procainamide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [15]
Propafenone DMPIBJK Moderate Altered metabolism of Infliximab due to Propafenone alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [15]
Flecainide DMSQDLE Moderate Altered metabolism of Infliximab due to Flecainide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [15]
Amiodarone DMUTEX3 Moderate Altered metabolism of Infliximab due to Amiodarone alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [15]
Ganciclovir DM1MBYQ Major Additive immunosuppressive effects by the combination of Infliximab and Ganciclovir. Virus infection [1A24-1D9Z] [12]
Trifluridine DMG2YBD Major Additive immunosuppressive effects by the combination of Infliximab and Trifluridine. Virus infection [1A24-1D9Z] [12]
Valganciclovir DMS2IUH Major Additive immunosuppressive effects by the combination of Infliximab and Valganciclovir. Virus infection [1A24-1D9Z] [12]
⏷ Show the Full List of 217 DDI Information of This Drug

References

1 Management of inflammatory bowel disease. Med J Aust. 2018 Sep 1;209(7):318-323.
2 Infliximab biosimilar-induced lupus nephritis: A case report. Mod Rheumatol Case Rep. 2023 Dec 29;8(1):74-76.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004).
4 Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
5 Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130.
6 Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
7 ClinicalTrials.gov (NCT00029042) Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
8 Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409.
9 Klotz U, Teml A, Schwab M: Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645-60. doi: 10.2165/00003088-200746080-00002.
10 Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.
11 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
12 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
13 Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
14 Cerner Multum, Inc. "Australian Product Information.".
15 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
18 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
19 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
20 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
21 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
22 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
23 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
24 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
25 Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
26 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
28 Product Information. Orencia (abatacept). Bristol-Myers Squibb, Princeton, NJ.
29 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
30 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.